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Variability of prasugrel antiplatelet effect 
in patients with acute coronary syndrome
ABSTRACT
Background. Many reports have demonstrated excessive variability in response to clopidogrel, the most 
commonly used P2Y12 receptor antagonist. Clopidogrel resistant patients are at increased risk of cardio-
vascular (CV) events. Prasugrel is a new P2Y12 inhibitor that provides greater and faster platelet inhibition 
and reduces CV events more effectively than clopidogrel. The aim of this study was to evaluate the variability 
and efficacy of prasugrel antiplatelet activity in patients presenting with acute coronary syndrome (ACS).
Materials and methods. The study was designed as a prospective, single-center, non-randomized, 
observational trial. Platelet reactivity (PR) was assessed with the VeryfyNow assay three times during 
hospitalization in forty-two patients undergoing percutaneous coronary intervention (PCI) for ACS and 
treated with standard doses of prasugrel.
Results. Platelet aggregation with prasugrel displayed relatively high variability. The platelet aggregation 
was lowest on the 3rd day of the treatment at 4 p.m. and was significantly different from the measurements 
obtained on the 3rd and 4th day in the morning (6.0 v. 8.5 U; p = 0.0005 and 6.0 v. 36.5 U; p < 0.00001, 
respectively), with the latter two differing significantly from each other (p = 0.002). All participants were 
successfully treated with prasugrel achieving PR < 208 PRU in each measurement, whereas 42.9–80.9% 
(depending on sampling point) of patients presented very low platelet activity. The subgroups of stable 
and persistent low PR included a higher percentage of active smokers (73.3 v. 40.7%; p = 0.04 and 80.0 v. 
43.8%; p = 0.04, respectively).
Conclusions. Prasugrel treatment is associated with high variability of PR. Nonetheless, prasugrel is a highly 
effective antiplatelet drug. Active smoking may predispose to strong and stable on-prasugrel platelet inhibition.
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Introduction
Platelet activation and aggregation play a pivotal role 
in the pathophysiology of acute coronary syndromes 
(ACS) [1]. Dual antiplatelet therapy (DAT) with aspirin 
and one of the platelet P2Y12 receptor antagonists 
reduces the risk of thrombotic events. This treatment 
is recommended in the management of patients with 
ACS and in patients after stent implantation [2–4]. 
Many reports have demonstrated excessive variability 
in response to clopidogrel, the most commonly used 
P2Y12 receptor antagonist, with a substantial rate 
of high on-treatment platelet reactivity (HTPR) [5–8]. 
Subjects with HTPR undergoing percutaneous coronary 
intervention (PCI) were shown to be at increased risk 
of cardiovascular (CV) events [6, 9]. Prasugrel is a new 
P2Y12 inhibitor that provides greater and faster platelet 
inhibition. It was shown to reduce CV events more ef-
fectively than clopidogrel in ACS patients undergoing 
PCI [10–12].
The aim of this study was to evaluate the inter-in-
dividual and intra-individual variability of prasugrel 
antiplatelet activity in patients with ACS treated 
with PCI.
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Materials and methods
Study design and population
This study was designed as a prospective, single- 
-center, non-randomized, observational trial. Forty-two 
consecutive patients admitted to the Department of 
Cardiology and Internal Medicine, Collegium Medi-
cum, Nicolaus Copernicus University, Bydgoszcz 
and treated with PCI for ACS were prospectively 
recruited into the study between 24 July 2013 and 
16 May 2014. The enrollment during first two days 
of hospitalization.
Study exclusion criteria included: 
 — age under 18 or over 75 years;
 — history of ischemic stroke or transient ischemic 
attack;
 — body weight below 60 kilograms;
 — severe liver failure (Child-Pugh class C);
 — need for prolonged use of oral anticoagulant ther-
apy, heparin or fondaparinux;
 — bleeding disorders (including thrombocytope-
nia < 100 × 103/µL);
 — anemia (defined as hemoglobin concentration 
< 10.0 g/dL);
 — active inflammation;
 — cardiogenic shock on admission;
 — heart failure class III and IV according to the New 
York Heart Association (NYHA) classification;
 — any contraindication to prasugrel due to increased 
risk of bleeding according to the attending physician.
All participants provided written informed consent. 
The study was approved by the Ethical Committee of 
the Nicolaus Copernicus University in accordance with 
the Declaration of Helsinki.
Pharmacotherapy
Directly after enrollment for the study patients 
were treated with a loading dose (60 mg) of prasugrel 
regardless of earlier antiplatelet treatment. The day of 
study inclusion was marked as “day 0”. Throughout 
the following hospitalization period prasugrel was 
continued in a single daily dose of 10 mg administered 
at 8.00 a.m. Concomitant medication in all patients in-
cluded aspirin (300 mg loading dose given immediately 
after establishing ACS diagnosis, followed by a 75 mg 
maintenance dose once daily), ramipril and bisoprolol 
in doses adjusted for resting heart rate and blood 
pressure, and atorvastatin (40 mg). All medications 
were administered at 8.00 a.m., except for atorvastatin, 
which was administered at 8.00 p.m. Gastroprotection 
with pantoprazole was given at the discretion of the 
attending physician. 
Measurement of platelet aggregation
Blood samples for platelet function testing were col-
lected at 3 time points: on the 3rd day of the maintenance 
treatment with 10 mg daily prasugrel dose (called “day 3”) 
at 8:00 a.m. (before prasugrel administration), on “day 
3” at 4:00 p.m. (8 h after the previous dose of prasugrel) 
and on the 4th day (called “day 4”) at 8:00 a.m. (prior 
to prasugrel administration). Prasugrel dosing regimen 
and timing of platelet testing are presented in Table 1.
Blood samples for platelet reactivity (PR) assess-
ment were drawn through a short venous catheter 
inserted into a forearm vein. Platelet function testing 
was performed with the VeryfyNow (Accumetrics Inc, 
San Diego, CA) point-of-care P2Y12 function assay. 
The results are reported in P2Y12 reaction unit (PRU). 
According to the previous studies, PRU > 208 was 
considered HTPR associated with an increased risk of 
thrombotic events [13, 14], while PRU < 30 PRU was 
considered LTPR (low on-treatment platelet reactivity) 
associated with an increased risk of bleeding compli-
cations [14–16].
Statistical analysis
Due to non-normal distribution of the investigated 
continuous variables as assessed with the Shapiro-Wilk 
test, continuous variables are reported as median val-
ues and their interquartile ranges. Intergroup compari-
sons were performed with the Mann-Whitney unpaired 
rank sum test, whereas the Wilcoxon matched-pairs 
rank sum test was applied for comparisons within 
the groups. Independent categorical variables were 
compared using the c2 test with the Yates’ correc-
tion if required. Multiple comparisons were analyzed 
with the ANOVA Friedman test. Values of two sided 
p < 0.05 were regarded as statistically significant; 
Table 1. Prasugrel dosing regimen and measurements 
of platelet activity
Day Hour Action taken
“Day 0” Administration of 60 mg of prasugrel
“Day 1” 8:00 a.m. Administration of 10 mg of prasugrel
“Day 2” 8:00 a.m. Administration of 10 mg of prasugrel
“Day 3” 8:00 a.m. Administration of 10 mg of prasugrel
8:00 a.m. Measurement of platelet reactivity
4:00 p.m. Measurement of platelet reactivity
“Day 4” 8:00 a.m. Administration of 10 mg of prasugrel
8:00 a.m. Measurement of platelet reactivity
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Table 2. Baseline characteristics of the study population 
(n = 42). Continuous variables are presented as median 
(lower quartile–upper quartile) while categorical variables 
are presented as numbers (percent)
Variable Value
Age (years) 56.0 (52.0–62.0)
Gender (male/female) 38 (90.5%)/4 (9.5%)
Final diagnosis
    NSTEMI/UA 12 (28.6%)
    STEMI 30 (71.4%)
Hypertension 23 (54.8%)
Diabetes mellitus 11 (26.2%)
Current smoker 22 (52.4%)
LVEF (%) 45.0 (38.0–50.0)
Lipid profile
    Total cholesterol [mg/dL] 224.0 (190.0–244.0)
    LDL cholesterol [mg/dL] 152.0 (119.0–174.0)
    HDL cholesterol [mg/dL] 50.0 (39.5–56.5)
    Triglycerides [mg/dL] 95.0 (69.0–145.0)
PLT [103/µL] 201.5 (173.0–243.0)
MPV [fL] 11.4 (10.6–11.8)
Proton pump inhibitor 
administration
12 (28.6%)
GFR [ml/min/1.73 m2] 99.5 (90.5–108.5)
GFR — glomerular filtration rate; HDL — high-density lipoprotein; LDL 
— low-density lipoprotein; LVEF — left ventricular ejection fraction; 
MPV — mean platelet volume; NSTEMI — non ST-segment elevation 
myocardial infarction; PLT — platelets; STEMI — ST-segment elevation  
myocardial infarction; UA — unstable angina
Figure 1. Diurnal and day-to-day variation of platelet 
aggregation as assessed with the Veryfy Now P2Y12 assay. 
Statistical significance p values for comparisons of two 
sampling points are presented on the figure. Statistical 
significance for inter-measurement heterogeneity at three 
time points is < 0.00001
ments obtained at different sampling points. The 
lowest platelet reactivity was observed on day 3 at 
4:00 p.m. and differed significantly as compared with 
reactivity measured on day 3 at 8:00 a.m. (6.0 [3.0–
–14.0] v. 8.5 [4.0–40.0] U; p = 0.0005), and on day 
4 at 8:00 a.m. (6.0 [3.0–14.0] v. 36.5 [6.0–55.0] U; 
p < 0.00001). There was also a significant day-to-
day difference in the morning platelet reactivity. The 
morning platelet reactivity was higher on day 4 than on 
day 3 (36.5 [6.0–55.0] v. 8.5 [4.0–40.0] U; p = 0.002). 
The ANOVA Friedman test confirmed a significant 
heterogeneity in the platelet reactivity assessed 
at different sampling points (p < 0.00001; Fig. 1). 
Intra-individual platelet aggregation variability is also 
well depicted when the measurements of individual 
patients are followed (Fig. 2).
All study participants were effectively treated with 
prasugrel during hospitalization (PRU < 208 at each 
measurement point). LTPR was observed in 77 out of 
126 measurements (61.1%). The highest prevalence 
of LTPR was found on day 3 at 4:00 p.m. (80.9%), 
while the lowest prevalence of LTPR was seen on 
day 4 at 8.00 a.m. (42.9%) (Fig. 3). In 15 subjects 
(35.7%) LTPR was observed at all three measurement 
points. When this subset of patients was compared 
with subjects who had at least one platelet aggregation 
measurement within therapeutic range, a statistically 
higher percentage of active smokers was found in the 
persistent LTPR group (73.3 v. 40.7%; 0.04). There 
were also tendencies for lower age (54.0 [51.0–58.0] 
v. 59.0 [53.0–66.0] years; p = 0.051) and higher 
high-density lipoprotein (HDL) cholesterol concen-
0.05 ≤ p < 0.1 was considered a trend towards statisti-
cal significance. The statistical analysis was carried out 
using the Statistica 10.0 statistical software (StatSoft, 
Tulsa, USA).
Results
The baseline characteristics of the study popu-
lation are presented in Table 2. We observed high 
inter-individual and intra-individual variability of plate-
let reactivity on prasugrel. Inter-individual variability, 
especially at the morning sampling points, is well 
reflected by broad interquartile (day 3: 4.0–40.0; day 4: 
6.0–55.0) and non-outlier ranges (day 3: 0.0–93.0; day 
4:1.0–127.0) (Fig. 1). In contrast, in the afternoon the 
dispersion of the results of platelet reactivity assess-
ment markedly decreased (3.0–14.0 and 0.0–25.0, 
respectively).
High intra-individual variability was reflected by 
huge differences in the platelet reactivity measure-
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Figure 3. Prevalence of low on-treatment platelet reactivity 
(LTPR) at each sampling point
Figure 2. Diurnal and day-to-day platelet aggregation 
variation of individual patients as assessed by the 
VeryfyNow P2Y12 assay
Table 3. Comparison of characteristics of patients with and without persistent low on-treatment platelet reactivity. 
Continuous variables are presented as median (lower quartile-upper quartile) while categorical variables are presented 
as numbers (percent) 
Variable
LTPR in all three measurements 
(n=15)
At least one measurement of PR 
within therapeutic range (n=37) p
Age (years) 54.0 (51.0–58.0) 59.0 (53.0–66.0) 0.051
Gender (male/female) 15 (100.0%)/0 (0.0%) 23 (85.2%)/4 (14.8%) 0.31
Final diagnosis
    NSTEMI/UA 4 (26.7%) 8 (29.6%) 0.83
    STEMI 11 (73.3%) 19 (70.4%)
Hypertension 7 (46.7%) 16 (59.3%) 0.43
Diabetes mellitus 3 (20.0%) 8 (29.6%) 0.75
Current smoker 11 (73.3%) 11 (40.7%) 0.04
LVEF (%) 45.0 (40.0–50.0) 40.0 (38.0–50.0) 0.51
Lipid profile
    Total cholesterol [mg/dL] 241.0 (191.0–263.0) 218.0 (187.0–236.0) 0.22
    LDL cholesterol [mg/dL] 152.0 (119.0–176.0) 153.0 (123.0–172.0) 0.99
    HDL cholesterol [mg/dL] 52.5 (47.0–58.0) 46.5 (36.0–55.0) 0.07
    Triglycerides [mg/dL] 115.5 (82.0–152.0) 93.0 (69.0–143.0) 0.44
PLT [103/µL] 214.0 (188.0–243.0) 191.5 (169.0–250.0) 0.58
MPV [fL] 11.4 (10.3–12.1) 11.4 (10.7–11.8) 1.00
Proton pump inhibitor administration 5 (33.3%) 7 (25.9%) 0.88
GFR [ml/min/1.73 m2] 100.0 (96.0–114.0) 99.0 (89.0–108.0) 0.40
GFR — glomerular filtration rate; HDL — high-density lipoprotein; LDL — low-density lipoprotein; LTPR — low on-treatment platelet reactivity; 
LVEF — left ventricular ejection fraction; MPV — mean platelet volume; NSTEMI — non ST-segment elevation myocardial infarction; PLT — platelets;  
PR — platelet reactivity; STEMI — ST-segment elevation myocardial infarction; UA — unstable angina
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Table 4. Comparison of characteristics of patients with and without stable platelet reactivity. Continuous variables are 
presented as median (lower quantile–upper quantile) while categorical variables are presented as numbers (percent)
Variable PR fluctuations < 5 PRU (n = 10) PR fluctuations ≥ 5 PRU (n = 32) p
Age (years) 54.5 (51.0–58.0) 56.5 (52.5–64.5) 0.23
Gender (male/female) 10 (100.0%)/0 (0.0%) 28 (87.5%)/4 (12.5%) 0.58
Final diagnosis
    NSTEMI/UA 2 (20.0%) 10 (31.3%) 0.77
    STEMI 8 (80.0%) 22 (68.7%)
Hypertension 3 (30.0%) 20 (62.5%) 0.07
Diabetes mellitus 0 (0.0%) 11 (34.4%) 0.08
Current smoker 8 (80.0%) 14 (43.8%) 0.04
LVEF (%) 45.0 (40.0-50.0) 42.5 (36.5-50.0) 0.39
Lipid profile
    Total cholesterol [mg/dL] 232.0 (192.0–263.0) 218.0 (187.0–236.0) 0.32
    LDL cholesterol [mg/dL] 152.0 (123.0–176.0) 152.5 (112.0–174.0) 0.89
    HDL cholesterol [mg/dL] 52.5 (48.0–53.0) 47.0 (37.0–57.0) 0.22
    Triglycerides [mg/dL] 110.0 (82.0–133.0) 194.0 (172.5–244.5) 0.71
PLT [103/µL] 214.0 (188.0–242.0) 194.0 (172.5–244.5) 0.76
MPV [fL] 11.3 (10.6–12.2) 11.4 (10.7–11.6) 0.60
Proton pump inhibitor 
administration
3 (30.0%) 9 (28.1%) 0.77
GFR [ml/min/1.73 m2] 100.5 (96.0–114.0) 97.5 (89.0–108.0) 0.30
GFR — glomerular filtration rate; HDL — high-density lipoprotein; LDL — low-density lipoprotein; LVEF — left ventricular ejection fraction;  
MPV — mean platelet volume; NSTEMI — non ST-segment elevation myocardial infarction; PLT — platelets; PR — platelet reactivity;  
STEMI — ST-segment elevation myocardial infarction; UA — unstable angina
tration (52.5 [47.0–58.0] v. 46.5 [36.0–55.0] mg/dL; 
p = 0.07) in this group (Tab. 3). Interestingly, the 
persistent LTPR subset of patients comprised only 
men, while all 4 women participating in the study had 
at least one platelet reactivity measurement within 
normal range. This difference however was not sta-
tistically significant, which may be due to the small 
representation of women in our study.
Despite generally high variability in diurnal and day-
to-day variations in platelet reactivity observed in our 
study we found 10 patients (23.8%) with fluctuations 
in VeryfyNow P2Y12 assay results below 5 PRU. Pa-
tients with the stable platelet function measurements 
significantly more often were active smokers (80.0 v. 
43.8%; p = 0.04) and displayed tendencies for lower 
prevalence of hypertension (30.0 v. 62.5%; p = 0.07) 
and diabetes (0.0 v. 34.4%; p = 0.08) (Tab. 4). 
All 4 women were in the higher PR fluctuation group, 
however this difference in gender distribution was 
statistically insignificant.
Platelet reactivity assessed with the VeryfyNow 
P2Y12 assay at each sampling point was unrelated to 
platelet count or mean platelet volume.
Discussion
Efficient and stable platelet inhibition is the corner-
stone of the treatment for patients with ACS and/or 
undergoing PCI. Prasugrel provides a more potent and 
stable antiplatelet effect when compared with clopidogrel 
[17, 18]. However, the main finding of our study is the 
relatively high inter-individual and intra-individual variabil-
ity of platelet reactivity as assessed with the VeryfyNow 
P2Y12 assay among patients treated with a maintenance 
dose of prasugrel in the stable phase of ACS (Fig. 1, Fig. 2). 
Taking into account the relatively small population 
included in our study, significant differences of diurnal 
and day-to-day aggregation proved the existence of 
substantial variability. However, the analysis of data pre-
sented in Figure 2 leads to a conclusion that even with 
the prominent intra-individual differences in aggregation 
there is a subgroup of patients presenting a stable and 
relatively low level of platelet reactivity. Further analysis 
revealed that 10 patients with low PR fluctuations, below 
5 PRU, more often were active smokers. Moreover, those 
patients tended to have a lower prevalence of diabetes 
mellitus and hypertension (Tab. 4).
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Diabetes mellitus is associated with a chronic inflam-
matory state promoting platelets hyperactivity [19, 20]. 
Several studies showed resistance to a conventional 
antiplatelet therapy with aspirin and clopidogrel in 
diabetic patients [2, 20]. Prasugrel has been proven 
to be more effective than clopidogrel in both diabetic 
and non-diabetic subjects [21]. This pharmacodynamic 
effectiveness translated into a better clinical outcome in 
patients treated with prasugrel compared with clopido-
grel in the TRITON-TIMI 38 study [10]. The composite 
ischemic event rate with prasugrel was diminished by 
14% in non-diabetic patients, by 26% in non-insulin- 
-treated diabetics, and by 37% in those treated with 
insulin [22].
Despite superior antiplatelet potency of prasugrel its 
effect remains suboptimal in some subsets of patient. 
Diabetes is one of the strongest factors of high on-pra-
sugrel platelet reactivity [23, 24]. Interestingly, in our 
population none of 11 diabetic patients displayed low 
PRU fluctuation. This suggests that diabetes is a risk 
factor not only for HTPR, but also for higher intra-indi-
vidual variability.
Hypertension was also identified as a risk factor of as-
pirin and clopidogrel resistance in some studies [25, 26]. 
Recently, Verdoia et al. showed that hypertension 
may also be a risk factor for ticagrelor non-respon-
siveness. Among other risk factors, hypertension was 
significantly associated with high platelet reactivity in 
the univariate analysis. However, age ≥ 70 years, con-
comitant therapy with beta-blockers and platelets count 
were the only independent predictors of high on-tica-
grelor platelet reactivity in the multivariate model [27]. 
Also retrospective analysis conducted by Bae et al. 
and a recent registry of PCI-treated patients did not 
indicate hypertension as a factor of high on-prasugrel 
platelet reactivity [23, 24]. In our study, a tendency for 
lower hypertension prevalence in the stable PR subset 
of patients was revealed, suggesting that hypertension 
might cause some variability in antiplatelet response. 
It is a well-known fact that antiplatelet effica-
cy of clopidogrel is higher in smokers than in 
non-smokers. In a study conducted in 377 patients 
with coronary artery disease who had undergone 
PCI and were treated with clopidogrel, significantly 
lower PR was found in smokers. An association 
between smoking and antiplatelet activity was 
also confirmed with the multivariate analysis [28]. 
Moreover, the clinical benefit of clopidogrel in prevent-
ing cardiovascular events was greater in smokers than 
in non-smokers, a phenomenon termed the “smoker’s 
paradox” [29, 30]. The explanation for this observation 
is cytochrome P 450 (CYP) 1A2 and 2B6 induction 
by cigarette smoking which results in a greater active 
metabolite generation [31]. Prasugrel undergoes less 
complex metabolization without involving CYP1A2 and 
therefore its efficacy should not be influenced by the 
smoking status [32]. However, a pharmacokinetic and 
pharmacodynamic study conducted by Gurbel et al. 
showed slightly stronger platelet inhibition by pras-
ugrel in smokers than non-smokers. This study also 
confirmed stronger antiplatelet potency of clopidogrel 
amongst smokers [32]. Our results suggest that the 
antiplatelet effect of prasugrel is more stable in smokers.
Although the subgroup of low PR fluctuation in our 
study consisted exclusively of men, this may be by 
chance, since our study population comprised only 
4 women. To draw any conclusions regarding the 
platelet response variability in relation to gender, a study 
with an adequate number of female participants should 
be conducted.
We observed PR less than 208 PRU in every platelet 
measurement performed during the study. The treat-
ment with clopidogrel, a still widely used second gener-
ation P2Y12 receptor blocker, results in an inadequate 
platelet inhibition in approximately one-third of patients 
with ACS [33]. Newer third generation P2Y12 antago-
nists, such as prasugrel, showed more effective platelet 
inhibition [12, 34, 35]. In a study by Alexopoulos et al., 
27 STEMI patients treated with prasugrel presented 
11.5% HTPR 6 h after loading dose administration and 
0% 5 days after the treatment initiation, as assessed with 
the VeryfyNow P2Y12 assay [36]. Similarly, in a study 
conducted by Laine et al. with 44 STEMI patients treated 
with prasugrel, HTPR measured 6–12 h after a loading 
dose of prasugrel and defined as VASP index above or 
equal to 50%, was reported in 4 patients (9,1%) [37]. 
Prasugrel was also shown to be effective in 44 ACS 
patients exhibiting HTPR following a clopidogrel loading 
dose. The rate of HTPR after 15 days of the maintenance 
treatment with prasugrel was only 2.4% in this high risk 
population [38].
On the other hand, up to 80.9% of patients en-
rolled into our study presented PR < 30 PRU, a level 
which has been shown to increase the risk of bleeding 
complications [14–16]. Our results are consistent with 
the study conducted by Laine et al., with the latter 
showing a 63.6% incidence of LTPR (defined as VASP 
index ≤ 16%) measured 6 to 12 h after prasugrel loading 
dose administration [37]. A lower prevalence of LTPR 
(using the same VASP index ≤ 16% criterion), equal to 
27.9% of patients, was reported by Bonello et al., with 
a concomitant 4.7-fold higher rate of bleeding events 
during a 1-year follow-up (15.6% v. 3.3%) [15]. In another 
study utilizing the VeryfyNow P2Y12 assay and the same 
cut-off point as in our study (< 30 PRU), the LTPR rate 
after 15 days of prasugrel treatment was 45.6% [39].
More than one-third of our population had persistent 
LTPR (PR < 30 PRU in all three measurements). We 
believe that this subgroup of patients is of remarkably 
high risk of bleeding complications. Identifying such 
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individuals and switching to less potent clopidogrel, 
as proposed by Kerneis et al., might be a reasonable 
option. However, this approach needs to be validated 
in large clinical trials as it may lead to ischemic events 
in clopidogrel non-responders [39]. 
In our study, patients with persistent LTPR more 
often were smokers which seems to confirm the stable 
and high antiplatelet potency of prasugrel in tobacco 
users as discussed above. As expected, patients from 
this group tended to be younger, as advanced age is 
a known risk factor of HTPR [8, 27].
Interestingly, patients with persistent LTPR present-
ed a tendency for higher HDL cholesterol concentra-
tions. Similar results regarding the association between 
clopidogrel resistance and lower HDL concentrations were 
reported for Jordanian and Serbian populations [26, 40]. 
Limitations 
Several limitations of our study should be acknowl-
edged. Firstly, only one method of platelet function as-
sessment was applied. Secondly, the study population 
size was small. Thirdly, the spectrum of data acquired 
by the researchers did not include some variables bear-
ing potential impact on on-treatment platelet reactivity 
(e.g. inflammatory markers).
Conclusions
Our study showed relatively high inter- and intra-in-
dividual variability of platelet reactivity among patients 
in the stable phase of ACS, treated with a maintenance 
dose of prasugrel. Additionally, we pointed out high an-
tiplatelet effectiveness of prasugrel, as all PR measure-
ments were below the threshold indicating high throm-
botic risk and two-thirds of the PR measurements were 
below the threshold of high bleeding risk. Active smok-
ing might predispose to strong and stable on-prasugrel 
platelet inhibition.
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